查看購物車
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1999103

黃體素市場：按產品類型、適應症、給藥途徑和最終用戶分類的全球市場預測 – 2026-2032 年

Progesterone Market by Product Type, Indication, Route Of Administration, End User - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 191 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

2025 年孕酮市場價值 16.8 億美元，預計到 2026 年將成長至 19.1 億美元，複合年成長率為 14.58%，到 2032 年將達到 43.6 億美元。

主要市場統計數據
基準年 2025 16.8億美元
預計年份：2026年 19.1億美元
預測年份 2032 43.6億美元
複合年成長率 (%) 14.58%

全面概述孕酮的臨床重要性、其製劑的演變、法規環境及其對治療和商業策略的影響。

孕酮仍然是生殖健康和治療管理中的關鍵激素，其臨床應用範圍廣泛，包括避孕、不孕症治療和荷爾蒙補充療法。孕酮在調節月經週期、維持懷孕和調節子宮內膜反應方面的生化作用，使其在臨床上持續受到關注，並推動了製劑科學和給藥途徑最佳化方面的研究。

不斷發展的臨床實踐、監管重點、劑量創新和生產策略如何重新定義整個孕酮生態系統的價值創造。

黃體素市場的發展並非僅僅體現在產品分階段的更新換代，而是反映了臨床實踐、生產製造以及整個商業模式的系統性變革。藥物傳遞技術的進步推動了局部陰道給藥療法在子宮內膜保護和不孕症治療中的廣泛應用，同時注射劑和皮下製劑也在不斷改進，以實現更可預測的藥物動力學和更高的患者便利性。

積極主動管理關稅變化對孕酮供應鏈和採購趨勢的累積營運和合約影響的策略。

為應對計劃於2025年實施的關稅調整和貿易政策更新，製造商、經銷商和醫療保健系統必須重新評估其與孕酮採購和製劑生產相關的供應鏈的韌性和成本結構。關稅調整可能會影響活性成分、進口製劑成分和成品的採購，進而對籌資策略和合約談判產生連鎖反應。

詳細的細分揭示了產品、適應症、給藥途徑和最終用戶之間的差異，這些差異會影響臨床區分、證據要求和商業性定位。

精細化的市場區隔觀點能夠清楚地揭示不同產品類型、適應症、給藥途徑和終端用戶的需求促進因素和創新機會。依產品類型分類，市場涵蓋天然和合成孕激素，其中合成孕激素可細分為Medroxyprogesterone和炔諾酮。這種細分會影響製劑選擇、專利格局和臨床醫生的偏好，因為天然和合成分子各自具有不同的藥理特性和生產流程要求。依適應症分類，用途包括避孕、生育治療和荷爾蒙補充療法。避孕類別進一步細分為複方口服避孕藥和黃體素單一療法；生育類別分為輔助生殖技術和促排卵；荷爾蒙補充療法分為子宮內膜保護和更年期管理。每種亞適應症都有其獨特的臨床終點、依從性挑戰和支付方考量，這些都會影響產品定位和證據要求。

區域法規、基礎設施和支付方趨勢決定了全球市場的准入途徑、分銷複雜性和策略重點。

區域趨勢對市場准入、監管合規和市場優先事項的影響至關重要，而這些因素對策略規劃至關重要。在美洲，醫療保健系統的整合、支付方主導的處方藥清單管理以及臨床指南的廣泛應用正在影響採購週期和對證據的期望。私人和公共支付者都會嚴格評估治療價值，並且通常要求提供新型或改良型孕酮製劑的比較數據和成本效益證據。在歐洲、中東和非洲，法規結構和報銷環境的多樣性既帶來了挑戰，也帶來了機會。一些司法管轄區的集中核准系統與各國特有的准入壁壘並存，這就需要根據當地情況客製化申請文件和相關人員參與策略。同時，在非洲和中東部分地區，供應鏈的脆弱性和基礎設施的限制凸顯了建立穩健的經銷夥伴關係和簡化供應鏈的必要性。

企業策略、夥伴關係和製造敏捷性如何塑造孕酮產品系列中的競爭定位，並實現基於證據的差異化。

黃體素領域的企業策略日益呈現創新投資、夥伴關係和生產靈活性三者融合的趨勢。原廠藥企業不斷研發新的製劑、給藥系統和聯合治療，以滿足未被滿足的醫療需求，並在以患者為中心的療效方面脫穎而出。同時，非專利生產商和合約研發生產機構（CDMO）也積極尋求監管途徑，以最佳化生產效率、縮短產品上市時間並證明生物等效性。

高階主管面臨的實際策略挑戰是如何將創新、監管應對力和供應鏈韌性與有針對性的商業化和夥伴關係模式結合。

產業領導者應採取綜合策略，協調研發投入、監管策略和供應鏈韌性，以降低風險並抓住機會。首先，應優先考慮旨在帶來臨床意義顯著獲益的製劑創新，例如改善局部給藥、減少全身副作用和提高遵守用藥，並調整臨床開發項目，以製定對支付方和醫療服務提供者至關重要的具體終點。其次，應加強監管和市場進入職能，並設計申請文件以支持在不同司法管轄區進行報銷談判，同時預見真實世界證據和上市後安全性監測要求的變化。

我們進行了一項混合方法調查，結合了相關人員訪談、監管和臨床文獻整合、專利檢索和情境分析，以確保獲得嚴謹而實用的見解。

本研究途徑結合了第一手資料和第二手資料，以獲得可靠且實用的見解。第一手資料包括對婦產科、生殖內分泌科和醫院藥房的臨床醫生進行訪談，以了解影響患者用藥依從性的臨床決策因素和考慮因素。此外，還與採購經理和監管事務專家進行了討論，以深入了解准入障礙和申請要求。第二手資料則整合了同儕審查文獻、監管指導文件、臨床指南、專利和安全資料庫，以全面檢驗臨床療效、安全性趨勢和智慧財產權趨勢。

臨床意義、劑量創新、監管壓力和營運準備的整合決定了整個孕酮價值鏈的競爭成功。

孕酮領域的不斷演變為創新者、生產者和醫療保健提供者帶來了機會和挑戰。孕酮在避孕、生育治療和更年期管理等方面的治療重要性確保了其持續受到臨床關注，而給藥技術的進步和對循證醫學日益成長的需求則為實現有意義的差異化提供了途徑。同時，貿易政策的變化、圍繞安全性和真實世界數據（REW）的監管力度加大以及不同地區獲取途徑的差異，都要求企業制定周密的戰略規劃。

目錄

第1章：序言

第2章：調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席體驗長觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 波特五力分析
  • PESTEL 分析
  • 市場展望
  • 上市策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

第8章：孕酮市場：依產品類型分類

  • 天然孕酮
  • 合成黃體素
    • Medroxyprogesterone
    • 去甲睾酮

第9章：孕酮市場：依適應症分類

  • 避孕藥
    • 複方口服避孕藥
    • 僅含黃體素的避孕藥
  • 不孕症治療
    • 輔助生殖技術
    • 誘導排卵
  • 荷爾蒙補充療法
    • 子宮內膜保護
    • 更年期管理

第10章：孕酮市場：依給藥途徑分類

  • 注射藥物
    • 肌肉內注射
    • 皮下注射
  • 口服
  • 經皮
  • 陰道使用
    • 陰道凝膠
    • 陰道栓劑
    • 陰道片

第11章：孕酮市場：依最終用戶分類

  • 診所
  • 家庭醫療保健
  • 醫院

第12章：孕酮市場：按地區分類

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第13章：孕酮市場：依組別分類

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第14章 孕酮市場：依國家分類

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第15章：美國黃體素市場

第16章：中國黃體素市場

第17章 競爭格局

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年
  • Abbott Laboratories
  • Balchem Corporation
  • BASF SE
  • Bayer AG
  • Caldic BV
  • Ferring International Center SA
  • Gnosis SpA
  • Laboratoires Besins International
  • Merck KGaA
  • Novartis AG
  • Pfizer Inc.
  • Pharmascience Inc.
  • Strides Pharma Science Limited
  • Teva Pharmaceutical Industries Ltd
Product Code: MRR-E3708867712D

The Progesterone Market was valued at USD 1.68 billion in 2025 and is projected to grow to USD 1.91 billion in 2026, with a CAGR of 14.58%, reaching USD 4.36 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 1.68 billion
Estimated Year [2026] USD 1.91 billion
Forecast Year [2032] USD 4.36 billion
CAGR (%) 14.58%

Comprehensive orientation to progesterone's clinical importance, formulation evolution, regulatory environment, and implications for therapeutic and commercial strategy

Progesterone remains a cornerstone hormone in reproductive health and therapeutic management, with a breadth of clinical applications that span contraception, fertility support, and hormone replacement therapy. Its biochemical role in regulating menstrual cycles, supporting gestation, and modulating endometrial response underpins sustained clinical demand and continued scientific interest in formulation science and route-of-administration optimization.

Recent advances in synthetic analogues, delivery systems, and companion diagnostics have reshaped the way clinicians prescribe and patients adhere to progesterone-based regimens. Concurrently, evolving regulatory expectations and heightened scrutiny around pharmacovigilance have compelled manufacturers and clinical stakeholders to prioritize safety data, bioequivalence strategies, and post-market surveillance. Transitioning from traditional tablet regimens toward diversified formats such as transdermal systems and vaginal formulations reflects both patient preference trends and the push for targeted local effects with reduced systemic exposure.

Taken together, these dynamics underscore a complex landscape in which therapeutic rationale, formulation innovation, and health-system adoption converge. The introduction sets the stage for a detailed examination of transformative shifts, policy impacts, segmentation nuances, regional differentials, corporate strategies, and practical recommendations for industry leaders seeking to navigate this evolving environment.

How evolving clinical practice, regulatory emphasis, delivery innovations, and manufacturing strategies are redefining value creation across the progesterone ecosystem

The progesterone landscape is shifting in ways that extend beyond incremental product updates and instead reflect systemic transformation across clinical practice, manufacturing, and commercial models. Advances in drug delivery technology have enabled localized vaginal therapies to gain traction for endometrial protection and fertility support, while injectable and subcutaneous options are being refined for more predictable pharmacokinetics and improved patient convenience.

Regulatory shifts are also driving change. Agencies are increasingly focused on real-world safety data and comparative effectiveness, prompting companies to invest in robust post-market evidence generation and to design trials that capture quality-of-life outcomes alongside traditional endpoints. Precision medicine trends intersect with reproductive health as clinicians seek to tailor progesterone therapies according to patient phenotypes and treatment goals, which in turn influences formulary decisions and prescribing patterns.

On the commercial front, strategic partnerships between clinical service providers and manufacturers are becoming more common, enabling integrated care pathways that bundle diagnostics, therapy, and monitoring. Additionally, manufacturing strategies are evolving to prioritize flexible capacity and geographic diversification to mitigate supply disruption risks. Taken together, these transformative shifts are redefining how value is created and captured in the progesterone ecosystem and setting new expectations for agility, evidence generation, and patient-centric design.

Anticipatory strategies for managing the cumulative operational and contractual effects of tariff changes on progesterone supply chains and procurement dynamics

The prospect of tariff changes and trade policy updates in 2025 compels manufacturers, distributors, and health systems to reassess supply chain resilience and cost structures associated with progesterone sourcing and finished-dose production. Tariff adjustments can affect active pharmaceutical ingredient procurement, imported formulation components, and finished product shipments, creating cascading implications for sourcing strategies and contract negotiations.

In anticipation of trade shifts, stakeholders are evaluating alternative supply routes, nearshoring options, and strategic stockholding to maintain continuity of care. Procurement teams are negotiating longer-term supply agreements and exploring multi-sourcing arrangements for critical intermediates to reduce dependence on single-country suppliers. Meanwhile, quality assurance and regulatory compliance considerations remain paramount as firms alter sourcing strategies, since changes in supplier geography often necessitate additional audits and regulatory filings.

Moreover, payer and provider networks are factoring potential cost variability into formulary management and purchasing decisions. Clinics and hospitals are engaging with manufacturers to understand the implications of customs duties on pricing and reimbursement dynamics, while home healthcare providers are exploring operational levers to absorb or mitigate incremental costs. The cumulative effect of tariff-related policy shifts is therefore not limited to unit economics; it influences contractual terms, inventory management, and longer-term strategic planning across the progesterone value chain.

Detailed segmentation reveals product, indication, delivery, and end-user distinctions that drive clinical differentiation, evidence needs, and commercial positioning

A granular segmentation lens clarifies demand drivers and innovation opportunities across product types, indications, delivery pathways, and end users. Based on product type, the market encompasses both Natural Progesterone and Synthetic Progesterone, with Synthetic Progesterone further differentiated into Medroxyprogesterone Acetate and Norethisterone; this differentiation has implications for formulation choices, patent landscapes, and clinician preference, as natural and synthetic molecules present distinct pharmacology and manufacturing considerations. Based on indication, applications span Contraceptives, Fertility Treatments, and Hormone Replacement Therapy, where the Contraceptives category further subdivides into Combined Oral Contraceptive and Progestin-Only Pill, the Fertility Treatments segment differentiates into Assisted Reproductive Technology and Ovulation Induction, and Hormone Replacement Therapy is parsed into Endometrial Protection and Menopause Management; each sub-indication carries unique clinical endpoints, adherence challenges, and payer considerations that influence product positioning and evidence needs.

Based on route of administration, delivery formats include Injectable, Oral, Transdermal, and Vaginal, with the Injectable option further classified into Intramuscular Injection and Subcutaneous Injection and Vaginal delivery explored through Vaginal Gel, Vaginal Suppository, and Vaginal Tablet; route-specific preferences affect bioavailability profiles, manufacturing complexity, and patient adherence outcomes. Based on end user, the landscape comprises Clinics, Home Healthcare, and Hospitals, and each setting imposes different procurement processes, cold-chain or handling requirements, and interactions with prescribers and payers. Integrating these segmentation dimensions reveals areas of unmet need where formulation innovation, targeted clinical evidence, and tailored commercial strategies can unlock value and improve patient experience.

Region-specific regulatory, infrastructure, and payer dynamics that determine access pathways, distribution complexity, and strategic priorities across global markets

Regional dynamics shape access, regulatory navigation, and market priorities in ways that are essential for strategic planning. In the Americas, health-system consolidation, payer-driven formulary management, and a high degree of clinical guideline uptake influence procurement cycles and evidence expectations; private and public payers closely evaluate therapeutic value and often require comparative data or cost-effectiveness rationale for new or reformulated progesterone products. In Europe, Middle East & Africa, a heterogeneous mix of regulatory frameworks and reimbursement environments creates both challenges and opportunities: centralized approvals in some jurisdictions coexist with country-level access hurdles that require locally tailored dossiers and stakeholder engagement strategies. Meanwhile, in parts of Africa and the Middle East, supply chain fragility and infrastructure constraints underline the need for robust distribution partnerships and simplified delivery formats.

In the Asia-Pacific region, rapid growth in clinical services, expanding fertility-care infrastructure, and progressive regulatory reform in several markets are driving demand for diverse progesterone formulations. The region also exhibits strong manufacturing capabilities for active ingredients and generics, presenting opportunities for contract manufacturing and cost-competitive production. Across all regions, differences in cultural attitudes toward reproductive health, prescribing norms, and patient preferences necessitate nuanced market-entry plans and region-specific evidence generation, while cross-regional lessons on technology adoption and care models can inform scalable strategies.

How corporate strategies, partnerships, and manufacturing agility are shaping competitive positioning and enabling evidence-driven differentiation in progesterone portfolios

Corporate strategies in the progesterone sector are increasingly characterized by a blend of innovation investment, partnership formation, and manufacturing agility. Innovator companies continue to advance novel formulations, delivery systems, and combination therapies to address unmet clinical needs and differentiate on patient-centric outcomes. At the same time, generic manufacturers and contract development and manufacturing organizations are optimizing production efficiencies and pursuing regulatory pathways that demonstrate bioequivalence while minimizing time-to-market.

Strategic collaborations between pharmaceutical firms, specialty compounding providers, and clinical service networks are becoming more prevalent as stakeholders seek to deliver integrated care solutions that include diagnostics, therapeutics, and adherence support. Companies are also investing in real-world evidence capabilities and pharmacovigilance infrastructure to meet heightened regulatory expectations and to support payer negotiations. In parallel, some firms are focusing on geographic diversification of manufacturing and warehousing to reduce trade-related risk and to comply with localized regulatory requirements. Competitive differentiation increasingly depends on a company's ability to combine clinical credibility, supply reliability, and commercial agility, while aligning product portfolios with emerging treatment pathways and provider workflows.

Actionable strategic imperatives for executives to align innovation, regulatory readiness, and supply resilience with targeted commercialization and partnership models

Industry leaders should pursue integrated approaches that align research investment, regulatory strategy, and supply-chain resilience to capture opportunities while mitigating risk. First, prioritize formulation innovation targeted at clinically meaningful benefits such as improved local delivery, reduced systemic side effects, and enhanced adherence, and align clinical development programs to generate the specific endpoints payers and providers value. Second, strengthen regulatory and market-access functions to anticipate evolving requirements for real-world evidence and post-market safety monitoring, ensuring dossiers are designed to support reimbursement discussions across heterogeneous jurisdictions.

Third, invest in flexible manufacturing and diversified sourcing strategies to reduce exposure to trade disruptions and to shorten lead times for product introduction. Fourth, explore strategic partnerships with clinics, hospitals, and home-care providers to integrate therapy delivery with diagnostics and patient support services, thereby improving uptake and clinical outcomes. Fifth, develop targeted commercialization plans that reflect segmentation realities-product type, indication, route of administration, and end-user requirements-while applying regional insights to adapt messaging and evidence packages. By executing these coordinated actions, leaders can better navigate regulatory change, optimize value capture, and accelerate adoption across care settings.

Mixed-method research combining stakeholder interviews, regulatory and clinical literature synthesis, patent review, and scenario analysis to ensure rigorous and actionable insights

The research approach combined primary qualitative engagement with secondary synthesis to derive robust, practice-oriented findings. Primary research included interviews with clinicians across obstetrics, gynecology, reproductive endocrinology, and hospital pharmacy to capture clinical decision drivers and patient adherence considerations, supplemented by discussions with procurement leaders and regulatory affairs specialists to understand access barriers and submission requirements. Secondary research synthesized peer-reviewed literature, regulatory guidance documents, clinical guideline statements, and patent and safety databases to triangulate clinical efficacy, safety trends, and intellectual property dynamics.

Analytical methods involved cross-validation of interview insights with document-based evidence, thematic coding to identify recurring commercial and clinical themes, and scenario analysis to explore supply-chain and policy contingencies. Quality control measures included source verification, expert peer review of interpretation, and adherence to transparent documentation practices to ensure reproducibility of findings. Wherever possible, regional granularity was derived by mapping regulatory frameworks and provider infrastructures against clinical practice patterns to produce actionable, jurisdiction-aware recommendations.

Synthesis of clinical relevance, delivery innovation, regulatory pressure, and operational readiness that determines competitive success across the progesterone value chain

The evolving progesterone landscape presents simultaneous opportunities and responsibilities for innovators, manufacturers, and care providers. Therapeutic relevance across contraception, fertility care, and menopause management ensures continued clinical focus, while advancements in delivery technology and evidence expectations create pathways for meaningful differentiation. At the same time, trade policy shifts, regulatory intensification around safety and real-world evidence, and regional heterogeneity in access mechanisms require deliberate strategic planning.

Synthesis of segmentation, regional, and corporate dynamics highlights that successful offerings will integrate clear clinical value, supply reliability, and adaptable commercialization strategies that reflect end-user realities. Companies that invest in targeted formulation work, evidence generation aligned to payer needs, and manufacturing flexibility will be positioned to respond to clinician preferences and patient expectations. Ultimately, the clinical utility of progesterone must be matched by commercial models and operational capabilities that deliver consistent access, transparent value propositions, and measurable outcomes in diverse care environments.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Progesterone Market, by Product Type

  • 8.1. Natural Progesterone
  • 8.2. Synthetic Progesterone
    • 8.2.1. Medroxyprogesterone Acetate
    • 8.2.2. Norethisterone

9. Progesterone Market, by Indication

  • 9.1. Contraceptives
    • 9.1.1. Combined Oral Contraceptive
    • 9.1.2. Progestin-Only Pill
  • 9.2. Fertility Treatments
    • 9.2.1. Assisted Reproductive Technology
    • 9.2.2. Ovulation Induction
  • 9.3. Hormone Replacement Therapy
    • 9.3.1. Endometrial Protection
    • 9.3.2. Menopause Management

10. Progesterone Market, by Route Of Administration

  • 10.1. Injectable
    • 10.1.1. Intramuscular Injection
    • 10.1.2. Subcutaneous Injection
  • 10.2. Oral
  • 10.3. Transdermal
  • 10.4. Vaginal
    • 10.4.1. Vaginal Gel
    • 10.4.2. Vaginal Suppository
    • 10.4.3. Vaginal Tablet

11. Progesterone Market, by End User

  • 11.1. Clinics
  • 11.2. Home Healthcare
  • 11.3. Hospitals

12. Progesterone Market, by Region

  • 12.1. Americas
    • 12.1.1. North America
    • 12.1.2. Latin America
  • 12.2. Europe, Middle East & Africa
    • 12.2.1. Europe
    • 12.2.2. Middle East
    • 12.2.3. Africa
  • 12.3. Asia-Pacific

13. Progesterone Market, by Group

  • 13.1. ASEAN
  • 13.2. GCC
  • 13.3. European Union
  • 13.4. BRICS
  • 13.5. G7
  • 13.6. NATO

14. Progesterone Market, by Country

  • 14.1. United States
  • 14.2. Canada
  • 14.3. Mexico
  • 14.4. Brazil
  • 14.5. United Kingdom
  • 14.6. Germany
  • 14.7. France
  • 14.8. Russia
  • 14.9. Italy
  • 14.10. Spain
  • 14.11. China
  • 14.12. India
  • 14.13. Japan
  • 14.14. Australia
  • 14.15. South Korea

15. United States Progesterone Market

16. China Progesterone Market

17. Competitive Landscape

  • 17.1. Market Concentration Analysis, 2025
    • 17.1.1. Concentration Ratio (CR)
    • 17.1.2. Herfindahl Hirschman Index (HHI)
  • 17.2. Recent Developments & Impact Analysis, 2025
  • 17.3. Product Portfolio Analysis, 2025
  • 17.4. Benchmarking Analysis, 2025
  • 17.5. Abbott Laboratories
  • 17.6. Balchem Corporation
  • 17.7. BASF SE
  • 17.8. Bayer AG
  • 17.9. Caldic B.V.
  • 17.10. Ferring International Center S.A.
  • 17.11. Gnosis S.p.A.
  • 17.12. Laboratoires Besins International
  • 17.13. Merck KGaA
  • 17.14. Novartis AG
  • 17.15. Pfizer Inc.
  • 17.16. Pharmascience Inc.
  • 17.17. Strides Pharma Science Limited
  • 17.18. Teva Pharmaceutical Industries Ltd

LIST OF FIGURES

  • FIGURE 1. GLOBAL PROGESTERONE MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL PROGESTERONE MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL PROGESTERONE MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL PROGESTERONE MARKET SIZE, BY PRODUCT TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL PROGESTERONE MARKET SIZE, BY INDICATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL PROGESTERONE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL PROGESTERONE MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL PROGESTERONE MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL PROGESTERONE MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL PROGESTERONE MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. UNITED STATES PROGESTERONE MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 12. CHINA PROGESTERONE MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL PROGESTERONE MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL PROGESTERONE MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL PROGESTERONE MARKET SIZE, BY NATURAL PROGESTERONE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL PROGESTERONE MARKET SIZE, BY NATURAL PROGESTERONE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL PROGESTERONE MARKET SIZE, BY NATURAL PROGESTERONE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL PROGESTERONE MARKET SIZE, BY SYNTHETIC PROGESTERONE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL PROGESTERONE MARKET SIZE, BY SYNTHETIC PROGESTERONE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL PROGESTERONE MARKET SIZE, BY SYNTHETIC PROGESTERONE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL PROGESTERONE MARKET SIZE, BY SYNTHETIC PROGESTERONE, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL PROGESTERONE MARKET SIZE, BY MEDROXYPROGESTERONE ACETATE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL PROGESTERONE MARKET SIZE, BY MEDROXYPROGESTERONE ACETATE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL PROGESTERONE MARKET SIZE, BY MEDROXYPROGESTERONE ACETATE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL PROGESTERONE MARKET SIZE, BY NORETHISTERONE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL PROGESTERONE MARKET SIZE, BY NORETHISTERONE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL PROGESTERONE MARKET SIZE, BY NORETHISTERONE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL PROGESTERONE MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL PROGESTERONE MARKET SIZE, BY CONTRACEPTIVES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL PROGESTERONE MARKET SIZE, BY CONTRACEPTIVES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL PROGESTERONE MARKET SIZE, BY CONTRACEPTIVES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL PROGESTERONE MARKET SIZE, BY CONTRACEPTIVES, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL PROGESTERONE MARKET SIZE, BY COMBINED ORAL CONTRACEPTIVE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL PROGESTERONE MARKET SIZE, BY COMBINED ORAL CONTRACEPTIVE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL PROGESTERONE MARKET SIZE, BY COMBINED ORAL CONTRACEPTIVE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL PROGESTERONE MARKET SIZE, BY PROGESTIN-ONLY PILL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL PROGESTERONE MARKET SIZE, BY PROGESTIN-ONLY PILL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL PROGESTERONE MARKET SIZE, BY PROGESTIN-ONLY PILL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL PROGESTERONE MARKET SIZE, BY FERTILITY TREATMENTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL PROGESTERONE MARKET SIZE, BY FERTILITY TREATMENTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL PROGESTERONE MARKET SIZE, BY FERTILITY TREATMENTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL PROGESTERONE MARKET SIZE, BY FERTILITY TREATMENTS, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL PROGESTERONE MARKET SIZE, BY ASSISTED REPRODUCTIVE TECHNOLOGY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL PROGESTERONE MARKET SIZE, BY ASSISTED REPRODUCTIVE TECHNOLOGY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL PROGESTERONE MARKET SIZE, BY ASSISTED REPRODUCTIVE TECHNOLOGY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL PROGESTERONE MARKET SIZE, BY OVULATION INDUCTION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL PROGESTERONE MARKET SIZE, BY OVULATION INDUCTION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL PROGESTERONE MARKET SIZE, BY OVULATION INDUCTION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL PROGESTERONE MARKET SIZE, BY HORMONE REPLACEMENT THERAPY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL PROGESTERONE MARKET SIZE, BY HORMONE REPLACEMENT THERAPY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL PROGESTERONE MARKET SIZE, BY HORMONE REPLACEMENT THERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL PROGESTERONE MARKET SIZE, BY HORMONE REPLACEMENT THERAPY, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL PROGESTERONE MARKET SIZE, BY ENDOMETRIAL PROTECTION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL PROGESTERONE MARKET SIZE, BY ENDOMETRIAL PROTECTION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL PROGESTERONE MARKET SIZE, BY ENDOMETRIAL PROTECTION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL PROGESTERONE MARKET SIZE, BY MENOPAUSE MANAGEMENT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL PROGESTERONE MARKET SIZE, BY MENOPAUSE MANAGEMENT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL PROGESTERONE MARKET SIZE, BY MENOPAUSE MANAGEMENT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL PROGESTERONE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL PROGESTERONE MARKET SIZE, BY INJECTABLE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL PROGESTERONE MARKET SIZE, BY INJECTABLE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL PROGESTERONE MARKET SIZE, BY INJECTABLE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL PROGESTERONE MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL PROGESTERONE MARKET SIZE, BY INTRAMUSCULAR INJECTION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL PROGESTERONE MARKET SIZE, BY INTRAMUSCULAR INJECTION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL PROGESTERONE MARKET SIZE, BY INTRAMUSCULAR INJECTION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL PROGESTERONE MARKET SIZE, BY SUBCUTANEOUS INJECTION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL PROGESTERONE MARKET SIZE, BY SUBCUTANEOUS INJECTION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL PROGESTERONE MARKET SIZE, BY SUBCUTANEOUS INJECTION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL PROGESTERONE MARKET SIZE, BY ORAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL PROGESTERONE MARKET SIZE, BY ORAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL PROGESTERONE MARKET SIZE, BY ORAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL PROGESTERONE MARKET SIZE, BY TRANSDERMAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL PROGESTERONE MARKET SIZE, BY TRANSDERMAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL PROGESTERONE MARKET SIZE, BY TRANSDERMAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL PROGESTERONE MARKET SIZE, BY VAGINAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL PROGESTERONE MARKET SIZE, BY VAGINAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL PROGESTERONE MARKET SIZE, BY VAGINAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL PROGESTERONE MARKET SIZE, BY VAGINAL, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL PROGESTERONE MARKET SIZE, BY VAGINAL GEL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL PROGESTERONE MARKET SIZE, BY VAGINAL GEL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL PROGESTERONE MARKET SIZE, BY VAGINAL GEL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL PROGESTERONE MARKET SIZE, BY VAGINAL SUPPOSITORY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL PROGESTERONE MARKET SIZE, BY VAGINAL SUPPOSITORY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL PROGESTERONE MARKET SIZE, BY VAGINAL SUPPOSITORY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL PROGESTERONE MARKET SIZE, BY VAGINAL TABLET, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL PROGESTERONE MARKET SIZE, BY VAGINAL TABLET, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL PROGESTERONE MARKET SIZE, BY VAGINAL TABLET, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL PROGESTERONE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL PROGESTERONE MARKET SIZE, BY CLINICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL PROGESTERONE MARKET SIZE, BY CLINICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL PROGESTERONE MARKET SIZE, BY CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL PROGESTERONE MARKET SIZE, BY HOME HEALTHCARE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL PROGESTERONE MARKET SIZE, BY HOME HEALTHCARE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 83. GLOBAL PROGESTERONE MARKET SIZE, BY HOME HEALTHCARE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 84. GLOBAL PROGESTERONE MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 85. GLOBAL PROGESTERONE MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 86. GLOBAL PROGESTERONE MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 87. GLOBAL PROGESTERONE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 88. AMERICAS PROGESTERONE MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 89. AMERICAS PROGESTERONE MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 90. AMERICAS PROGESTERONE MARKET SIZE, BY SYNTHETIC PROGESTERONE, 2018-2032 (USD MILLION)
  • TABLE 91. AMERICAS PROGESTERONE MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 92. AMERICAS PROGESTERONE MARKET SIZE, BY CONTRACEPTIVES, 2018-2032 (USD MILLION)
  • TABLE 93. AMERICAS PROGESTERONE MARKET SIZE, BY FERTILITY TREATMENTS, 2018-2032 (USD MILLION)
  • TABLE 94. AMERICAS PROGESTERONE MARKET SIZE, BY HORMONE REPLACEMENT THERAPY, 2018-2032 (USD MILLION)
  • TABLE 95. AMERICAS PROGESTERONE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 96. AMERICAS PROGESTERONE MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 97. AMERICAS PROGESTERONE MARKET SIZE, BY VAGINAL, 2018-2032 (USD MILLION)
  • TABLE 98. AMERICAS PROGESTERONE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 99. NORTH AMERICA PROGESTERONE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 100. NORTH AMERICA PROGESTERONE MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 101. NORTH AMERICA PROGESTERONE MARKET SIZE, BY SYNTHETIC PROGESTERONE, 2018-2032 (USD MILLION)
  • TABLE 102. NORTH AMERICA PROGESTERONE MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 103. NORTH AMERICA PROGESTERONE MARKET SIZE, BY CONTRACEPTIVES, 2018-2032 (USD MILLION)
  • TABLE 104. NORTH AMERICA PROGESTERONE MARKET SIZE, BY FERTILITY TREATMENTS, 2018-2032 (USD MILLION)
  • TABLE 105. NORTH AMERICA PROGESTERONE MARKET SIZE, BY HORMONE REPLACEMENT THERAPY, 2018-2032 (USD MILLION)
  • TABLE 106. NORTH AMERICA PROGESTERONE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 107. NORTH AMERICA PROGESTERONE MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 108. NORTH AMERICA PROGESTERONE MARKET SIZE, BY VAGINAL, 2018-2032 (USD MILLION)
  • TABLE 109. NORTH AMERICA PROGESTERONE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 110. LATIN AMERICA PROGESTERONE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 111. LATIN AMERICA PROGESTERONE MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 112. LATIN AMERICA PROGESTERONE MARKET SIZE, BY SYNTHETIC PROGESTERONE, 2018-2032 (USD MILLION)
  • TABLE 113. LATIN AMERICA PROGESTERONE MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 114. LATIN AMERICA PROGESTERONE MARKET SIZE, BY CONTRACEPTIVES, 2018-2032 (USD MILLION)
  • TABLE 115. LATIN AMERICA PROGESTERONE MARKET SIZE, BY FERTILITY TREATMENTS, 2018-2032 (USD MILLION)
  • TABLE 116. LATIN AMERICA PROGESTERONE MARKET SIZE, BY HORMONE REPLACEMENT THERAPY, 2018-2032 (USD MILLION)
  • TABLE 117. LATIN AMERICA PROGESTERONE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 118. LATIN AMERICA PROGESTERONE MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 119. LATIN AMERICA PROGESTERONE MARKET SIZE, BY VAGINAL, 2018-2032 (USD MILLION)
  • TABLE 120. LATIN AMERICA PROGESTERONE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 121. EUROPE, MIDDLE EAST & AFRICA PROGESTERONE MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 122. EUROPE, MIDDLE EAST & AFRICA PROGESTERONE MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 123. EUROPE, MIDDLE EAST & AFRICA PROGESTERONE MARKET SIZE, BY SYNTHETIC PROGESTERONE, 2018-2032 (USD MILLION)
  • TABLE 124. EUROPE, MIDDLE EAST & AFRICA PROGESTERONE MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 125. EUROPE, MIDDLE EAST & AFRICA PROGESTERONE MARKET SIZE, BY CONTRACEPTIVES, 2018-2032 (USD MILLION)
  • TABLE 126. EUROPE, MIDDLE EAST & AFRICA PROGESTERONE MARKET SIZE, BY FERTILITY TREATMENTS, 2018-2032 (USD MILLION)
  • TABLE 127. EUROPE, MIDDLE EAST & AFRICA PROGESTERONE MARKET SIZE, BY HORMONE REPLACEMENT THERAPY, 2018-2032 (USD MILLION)
  • TABLE 128. EUROPE, MIDDLE EAST & AFRICA PROGESTERONE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 129. EUROPE, MIDDLE EAST & AFRICA PROGESTERONE MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 130. EUROPE, MIDDLE EAST & AFRICA PROGESTERONE MARKET SIZE, BY VAGINAL, 2018-2032 (USD MILLION)
  • TABLE 131. EUROPE, MIDDLE EAST & AFRICA PROGESTERONE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 132. EUROPE PROGESTERONE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 133. EUROPE PROGESTERONE MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 134. EUROPE PROGESTERONE MARKET SIZE, BY SYNTHETIC PROGESTERONE, 2018-2032 (USD MILLION)
  • TABLE 135. EUROPE PROGESTERONE MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 136. EUROPE PROGESTERONE MARKET SIZE, BY CONTRACEPTIVES, 2018-2032 (USD MILLION)
  • TABLE 137. EUROPE PROGESTERONE MARKET SIZE, BY FERTILITY TREATMENTS, 2018-2032 (USD MILLION)
  • TABLE 138. EUROPE PROGESTERONE MARKET SIZE, BY HORMONE REPLACEMENT THERAPY, 2018-2032 (USD MILLION)
  • TABLE 139. EUROPE PROGESTERONE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 140. EUROPE PROGESTERONE MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 141. EUROPE PROGESTERONE MARKET SIZE, BY VAGINAL, 2018-2032 (USD MILLION)
  • TABLE 142. EUROPE PROGESTERONE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 143. MIDDLE EAST PROGESTERONE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 144. MIDDLE EAST PROGESTERONE MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 145. MIDDLE EAST PROGESTERONE MARKET SIZE, BY SYNTHETIC PROGESTERONE, 2018-2032 (USD MILLION)
  • TABLE 146. MIDDLE EAST PROGESTERONE MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 147. MIDDLE EAST PROGESTERONE MARKET SIZE, BY CONTRACEPTIVES, 2018-2032 (USD MILLION)
  • TABLE 148. MIDDLE EAST PROGESTERONE MARKET SIZE, BY FERTILITY TREATMENTS, 2018-2032 (USD MILLION)
  • TABLE 149. MIDDLE EAST PROGESTERONE MARKET SIZE, BY HORMONE REPLACEMENT THERAPY, 2018-2032 (USD MILLION)
  • TABLE 150. MIDDLE EAST PROGESTERONE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 151. MIDDLE EAST PROGESTERONE MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 152. MIDDLE EAST PROGESTERONE MARKET SIZE, BY VAGINAL, 2018-2032 (USD MILLION)
  • TABLE 153. MIDDLE EAST PROGESTERONE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 154. AFRICA PROGESTERONE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 155. AFRICA PROGESTERONE MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 156. AFRICA PROGESTERONE MARKET SIZE, BY SYNTHETIC PROGESTERONE, 2018-2032 (USD MILLION)
  • TABLE 157. AFRICA PROGESTERONE MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 158. AFRICA PROGESTERONE MARKET SIZE, BY CONTRACEPTIVES, 2018-2032 (USD MILLION)
  • TABLE 159. AFRICA PROGESTERONE MARKET SIZE, BY FERTILITY TREATMENTS, 2018-2032 (USD MILLION)
  • TABLE 160. AFRICA PROGESTERONE MARKET SIZE, BY HORMONE REPLACEMENT THERAPY, 2018-2032 (USD MILLION)
  • TABLE 161. AFRICA PROGESTERONE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 162. AFRICA PROGESTERONE MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 163. AFRICA PROGESTERONE MARKET SIZE, BY VAGINAL, 2018-2032 (USD MILLION)
  • TABLE 164. AFRICA PROGESTERONE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 165. ASIA-PACIFIC PROGESTERONE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 166. ASIA-PACIFIC PROGESTERONE MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 167. ASIA-PACIFIC PROGESTERONE MARKET SIZE, BY SYNTHETIC PROGESTERONE, 2018-2032 (USD MILLION)
  • TABLE 168. ASIA-PACIFIC PROGESTERONE MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 169. ASIA-PACIFIC PROGESTERONE MARKET SIZE, BY CONTRACEPTIVES, 2018-2032 (USD MILLION)
  • TABLE 170. ASIA-PACIFIC PROGESTERONE MARKET SIZE, BY FERTILITY TREATMENTS, 2018-2032 (USD MILLION)
  • TABLE 171. ASIA-PACIFIC PROGESTERONE MARKET SIZE, BY HORMONE REPLACEMENT THERAPY, 2018-2032 (USD MILLION)
  • TABLE 172. ASIA-PACIFIC PROGESTERONE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 173. ASIA-PACIFIC PROGESTERONE MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 174. ASIA-PACIFIC PROGESTERONE MARKET SIZE, BY VAGINAL, 2018-2032 (USD MILLION)
  • TABLE 175. ASIA-PACIFIC PROGESTERONE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 176. GLOBAL PROGESTERONE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 177. ASEAN PROGESTERONE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 178. ASEAN PROGESTERONE MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 179. ASEAN PROGESTERONE MARKET SIZE, BY SYNTHETIC PROGESTERONE, 2018-2032 (USD MILLION)
  • TABLE 180. ASEAN PROGESTERONE MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 181. ASEAN PROGESTERONE MARKET SIZE, BY CONTRACEPTIVES, 2018-2032 (USD MILLION)
  • TABLE 182. ASEAN PROGESTERONE MARKET SIZE, BY FERTILITY TREATMENTS, 2018-2032 (USD MILLION)
  • TABLE 183. ASEAN PROGESTERONE MARKET SIZE, BY HORMONE REPLACEMENT THERAPY, 2018-2032 (USD MILLION)
  • TABLE 184. ASEAN PROGESTERONE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 185. ASEAN PROGESTERONE MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 186. ASEAN PROGESTERONE MARKET SIZE, BY VAGINAL, 2018-2032 (USD MILLION)
  • TABLE 187. ASEAN PROGESTERONE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 188. GCC PROGESTERONE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 189. GCC PROGESTERONE MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 190. GCC PROGESTERONE MARKET SIZE, BY SYNTHETIC PROGESTERONE, 2018-2032 (USD MILLION)
  • TABLE 191. GCC PROGESTERONE MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 192. GCC PROGESTERONE MARKET SIZE, BY CONTRACEPTIVES, 2018-2032 (USD MILLION)
  • TABLE 193. GCC PROGESTERONE MARKET SIZE, BY FERTILITY TREATMENTS, 2018-2032 (USD MILLION)
  • TABLE 194. GCC PROGESTERONE MARKET SIZE, BY HORMONE REPLACEMENT THERAPY, 2018-2032 (USD MILLION)
  • TABLE 195. GCC PROGESTERONE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 196. GCC PROGESTERONE MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 197. GCC PROGESTERONE MARKET SIZE, BY VAGINAL, 2018-2032 (USD MILLION)
  • TABLE 198. GCC PROGESTERONE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 199. EUROPEAN UNION PROGESTERONE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 200. EUROPEAN UNION PROGESTERONE MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 201. EUROPEAN UNION PROGESTERONE MARKET SIZE, BY SYNTHETIC PROGESTERONE, 2018-2032 (USD MILLION)
  • TABLE 202. EUROPEAN UNION PROGESTERONE MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 203. EUROPEAN UNION PROGESTERONE MARKET SIZE, BY CONTRACEPTIVES, 2018-2032 (USD MILLION)
  • TABLE 204. EUROPEAN UNION PROGESTERONE MARKET SIZE, BY FERTILITY TREATMENTS, 2018-2032 (USD MILLION)
  • TABLE 205. EUROPEAN UNION PROGESTERONE MARKET SIZE, BY HORMONE REPLACEMENT THERAPY, 2018-2032 (USD MILLION)
  • TABLE 206. EUROPEAN UNION PROGESTERONE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 207. EUROPEAN UNION PROGESTERONE MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 208. EUROPEAN UNION PROGESTERONE MARKET SIZE, BY VAGINAL, 2018-2032 (USD MILLION)
  • TABLE 209. EUROPEAN UNION PROGESTERONE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 210. BRICS PROGESTERONE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 211. BRICS PROGESTERONE MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 212. BRICS PROGESTERONE MARKET SIZE, BY SYNTHETIC PROGESTERONE, 2018-2032 (USD MILLION)
  • TABLE 213. BRICS PROGESTERONE MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 214. BRICS PROGESTERONE MARKET SIZE, BY CONTRACEPTIVES, 2018-2032 (USD MILLION)
  • TABLE 215. BRICS PROGESTERONE MARKET SIZE, BY FERTILITY TREATMENTS, 2018-2032 (USD MILLION)
  • TABLE 216. BRICS PROGESTERONE MARKET SIZE, BY HORMONE REPLACEMENT THERAPY, 2018-2032 (USD MILLION)
  • TABLE 217. BRICS PROGESTERONE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 218. BRICS PROGESTERONE MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 219. BRICS PROGESTERONE MARKET SIZE, BY VAGINAL, 2018-2032 (USD MILLION)
  • TABLE 220. BRICS PROGESTERONE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 221. G7 PROGESTERONE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 222. G7 PROGESTERONE MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 223. G7 PROGESTERONE MARKET SIZE, BY SYNTHETIC PROGESTERONE, 2018-2032 (USD MILLION)
  • TABLE 224. G7 PROGESTERONE MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 225. G7 PROGESTERONE MARKET SIZE, BY CONTRACEPTIVES, 2018-2032 (USD MILLION)
  • TABLE 226. G7 PROGESTERONE MARKET SIZE, BY FERTILITY TREATMENTS, 2018-2032 (USD MILLION)
  • TABLE 227. G7 PROGESTERONE MARKET SIZE, BY HORMONE REPLACEMENT THERAPY, 2018-2032 (USD MILLION)
  • TABLE 228. G7 PROGESTERONE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 229. G7 PROGESTERONE MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 230. G7 PROGESTERONE MARKET SIZE, BY VAGINAL, 2018-2032 (USD MILLION)
  • TABLE 231. G7 PROGESTERONE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 232. NATO PROGESTERONE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 233. NATO PROGESTERONE MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 234. NATO PROGESTERONE MARKET SIZE, BY SYNTHETIC PROGESTERONE, 2018-2032 (USD MILLION)
  • TABLE 235. NATO PROGESTERONE MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 236. NATO PROGESTERONE MARKET SIZE, BY CONTRACEPTIVES, 2018-2032 (USD MILLION)
  • TABLE 237. NATO PROGESTERONE MARKET SIZE, BY FERTILITY TREATMENTS, 2018-2032 (USD MILLION)
  • TABLE 238. NATO PROGESTERONE MARKET SIZE, BY HORMONE REPLACEMENT THERAPY, 2018-2032 (USD MILLION)
  • TABLE 239. NATO PROGESTERONE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 240. NATO PROGESTERONE MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 241. NATO PROGESTERONE MARKET SIZE, BY VAGINAL, 2018-2032 (USD MILLION)
  • TABLE 242. NATO PROGESTERONE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 243. GLOBAL PROGESTERONE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 244. UNITED STATES PROGESTERONE MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 245. UNITED STATES PROGESTERONE MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 246. UNITED STATES PROGESTERONE MARKET SIZE, BY SYNTHETIC PROGESTERONE, 2018-2032 (USD MILLION)
  • TABLE 247. UNITED STATES PROGESTERONE MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 248. UNITED STATES PROGESTERONE MARKET SIZE, BY CONTRACEPTIVES, 2018-2032 (USD MILLION)
  • TABLE 249. UNITED STATES PROGESTERONE MARKET SIZE, BY FERTILITY TREATMENTS, 2018-2032 (USD MILLION)
  • TABLE 250. UNITED STATES PROGESTERONE MARKET SIZE, BY HORMONE REPLACEMENT THERAPY, 2018-2032 (USD MILLION)
  • TABLE 251. UNITED STATES PROGESTERONE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 252. UNITED STATES PROGESTERONE MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 253. UNITED STATES PROGESTERONE MARKET SIZE, BY VAGINAL, 2018-2032 (USD MILLION)
  • TABLE 254. UNITED STATES PROGESTERONE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 255. CHINA PROGESTERONE MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 256. CHINA PROGESTERONE MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 257. CHINA PROGESTERONE MARKET SIZE, BY SYNTHETIC PROGESTERONE, 2018-2032 (USD MILLION)
  • TABLE 258. CHINA PROGESTERONE MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 259. CHINA PROGESTERONE MARKET SIZE, BY CONTRACEPTIVES, 2018-2032 (USD MILLION)
  • TABLE 260. CHINA PROGESTERONE MARKET SIZE, BY FERTILITY TREATMENTS, 2018-2032 (USD MILLION)
  • TABLE 261. CHINA PROGESTERONE MARKET SIZE, BY HORMONE REPLACEMENT THERAPY, 2018-2032 (USD MILLION)
  • TABLE 262. CHINA PROGESTERONE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 263. CHINA PROGESTERONE MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 264. CHINA PROGESTERONE MARKET SIZE, BY VAGINAL, 2018-2032 (USD MILLION)
  • TABLE 265. CHINA PROGESTERONE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)